Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New drug duo aims to stop kidney transplant rejection

NCT ID NCT06918990

First seen Nov 01, 2025 · Last updated Jun 18, 2026 · Updated 38 times

Summary

This early-stage study tests two drugs, carfilzomib and belatacept, along with standard steroids and immune-suppressing medicines, to treat a type of kidney transplant rejection called antibody-mediated rejection. The goal is to see if this combination is safe and can reduce harmful antibodies or improve kidney function. About 25 kidney transplant recipients with signs of rejection will be followed for one year.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for KIDNEY TRANSPLANT REJECTION are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Cleveland Clinic

    NOT_YET_RECRUITING

    Cleveland, Ohio, 44195, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Duke University

    NOT_YET_RECRUITING

    Durham, North Carolina, 27710, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Mayo Clinic Arizona

    NOT_YET_RECRUITING

    Phoenix, Arizona, 85054, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • NYU Langone Health

    RECRUITING

    New York, New York, 10016, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Northwestern University, Feinberg School of Medicine

    NOT_YET_RECRUITING

    Chicago, Illinois, 60611, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • UCLA Medical Center (Site #: 71123)

    NOT_YET_RECRUITING

    Los Angeles, California, 90024, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of Alabama Medical Center

    NOT_YET_RECRUITING

    Birmingham, Alabama, 35294, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of Cincinnati

    NOT_YET_RECRUITING

    Cincinnati, Ohio, 45267, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of Wisconsin - Madison

    NOT_YET_RECRUITING

    Madison, Wisconsin, 53726, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Washington University

    NOT_YET_RECRUITING

    St Louis, Missouri, 63110, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

The condition(s) this trial relates to.

transplant rejection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.